TMEM171

Across TCGA pan-cancer cohorts, TMEM171 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM171 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM171 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM171 expression acts as an unfavorable survival marker.

HNSC, MESO, and CESC are the cancer types where TMEM171 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.156	0.743	.001	42	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
CESC	OS	Median	All	0.271	0.798	.010	6	view →
LUSC	OS	Median	II,III,IV	0.279	0.742	.032	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM171–HNSC (OS)

Open the HNSC breakdown →